Clinical Trials Browser

Phase 1 × OTHER × pomalidomide × Clear all

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Phase 1 Active not recruiting

Multiple Myeloma

NCT01198067 2025-09-04

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 1 Terminated

15 enrolled 12 charts

Waldenstrom Macroglobulinemia

NCT03143985 2024-05-24

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma

NCT01728259 2023-05-09

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Phase 1 Terminated

Immunoglobulin Light-chain Amyloidosis

NCT02569320 2021-06-15

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Phase 1 Completed

Multiple Myeloma

NCT04355039 2020-08-19

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT03015922 2020-01-22

MUKeleven

Phase 1 Unknown

Multiple Myeloma

NCT03657420 2019-08-14

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT01078974 2016-07-25

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Phase 1 Terminated

7 enrolled 8 charts

Waldenstrom Macroglobulinemia

NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Phase 1 Terminated

Amyloidosis, Neoplasms, Plasma Cell

NCT01889420 2015-07-31

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

1 enrolled 3 charts

Recurrence, Neoplasms, Plasma Cell

NCT00482521 2012-08-28

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific